Next Article in Journal
The Interplay between Liver and Adipose Tissue in the Onset of Liver Diseases: Exploring the Role of Vitamin Deficiency
Previous Article in Journal
Role of WISP1 in Stellate Cell Migration and Liver Fibrosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 13
Issue 19
10.3390/cells13191630
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cells 2020, 9(2), 481.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Pittala et al. The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus. Cells 2020, 9, 481

by
Srinivas Pittala
,
Idan Levy
,
Soumasree De
,
Swaroop Kumar Pandey
,
Nataly Melnikov
,
Tehila Hyman
and
Varda Shoshan-Barmatz
*
Department of Life Sciences and the National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
*
Author to whom correspondence should be addressed.
Cells 2024, 13(19), 1630; https://doi.org/10.3390/cells13191630
Submission received: 15 July 2024 / Accepted: 15 August 2024 / Published: 30 September 2024
Browse Figure
Versions Notes

Error in Figure

In the original publication [1], the image in Figure 1D is overlapping with Figure 1E [2]. The images have been inadvertently overleaped with previously published work. The corrected Figure 1D, R-Tf-D-LP4 has now been replaced with a different image, shown below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

References

  1. Pittala, S.; Levy, I.; De, S.; Kumar Pandey, S.; Melnikov, N.; Hyman, T.; Shoshan-Barmatz, V. The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus. Cells 2020, 9, 481. [Google Scholar] [CrossRef] [PubMed]
  2. Pittala, S.; Krelin, Y.; Kuperman, Y.; Shoshan-Barmatz, V. A Mitochondrial VDAC1-Based Peptide Greatly Suppresses Steatosis and NASH-Associated Pathologies in a Mouse Model. Mol. Ther. 2019, 27, 1848–1862. [Google Scholar] [CrossRef] [PubMed]
Cells 13 01630 g001
Figure 1. R-Tf-D-LP4 peptide-mediated inhibition of steatotic and non-alcoholic steatohepatitis (NASH) liver pathology in a STZ/HFD-32 mouse model. (A). Schematic presentation of the course of steatosis and NASH induced by a STZ/HFD-32 diet and the effect of R-Tf-D-LP4 peptide treatment. (B–D). Liver from mice fed with chow (normal diet), HFD-32, or HFD-32 and treated with the R-Tf-D-LP4 peptide (14 mg/kg) by i.v. injection every two days from Week 6 to 8 for steatosis and from Week 8 to 10 for NASH, as described in the Methods section. Mice were then sacrificed, livers were removed, photographed (B), and weighed (C) Results are means ± SEM (n = 10), (p **** ≤ 0.0001). Representative liver sections were stained with Oil Red O (D). Blood glucose level of mice was measured. Results are means ± SEM (n = 5–10; ** p ≤ 0.01, p **** ≤ 0.0001) (E).
Figure 1. R-Tf-D-LP4 peptide-mediated inhibition of steatotic and non-alcoholic steatohepatitis (NASH) liver pathology in a STZ/HFD-32 mouse model. (A). Schematic presentation of the course of steatosis and NASH induced by a STZ/HFD-32 diet and the effect of R-Tf-D-LP4 peptide treatment. (B–D). Liver from mice fed with chow (normal diet), HFD-32, or HFD-32 and treated with the R-Tf-D-LP4 peptide (14 mg/kg) by i.v. injection every two days from Week 6 to 8 for steatosis and from Week 8 to 10 for NASH, as described in the Methods section. Mice were then sacrificed, livers were removed, photographed (B), and weighed (C) Results are means ± SEM (n = 10), (p **** ≤ 0.0001). Representative liver sections were stained with Oil Red O (D). Blood glucose level of mice was measured. Results are means ± SEM (n = 5–10; ** p ≤ 0.01, p **** ≤ 0.0001) (E).
Cells 13 01630 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pittala, S.; Levy, I.; De, S.; Pandey, S.K.; Melnikov, N.; Hyman, T.; Shoshan-Barmatz, V. Correction: Pittala et al. The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus. Cells 2020, 9, 481. Cells 2024, 13, 1630. https://doi.org/10.3390/cells13191630

AMA Style

Pittala S, Levy I, De S, Pandey SK, Melnikov N, Hyman T, Shoshan-Barmatz V. Correction: Pittala et al. The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus. Cells 2020, 9, 481. Cells. 2024; 13(19):1630. https://doi.org/10.3390/cells13191630

Chicago/Turabian Style

Pittala, Srinivas, Idan Levy, Soumasree De, Swaroop Kumar Pandey, Nataly Melnikov, Tehila Hyman, and Varda Shoshan-Barmatz. 2024. "Correction: Pittala et al. The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus. Cells 2020, 9, 481" Cells 13, no. 19: 1630. https://doi.org/10.3390/cells13191630

APA Style

Pittala, S., Levy, I., De, S., Pandey, S. K., Melnikov, N., Hyman, T., & Shoshan-Barmatz, V. (2024). Correction: Pittala et al. The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus. Cells 2020, 9, 481. Cells, 13(19), 1630. https://doi.org/10.3390/cells13191630

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop